AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Drug: duvelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (Kinase)
Gene: PIK3CA
UniProt: P42336 (PK3CA_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 5.8
Action type: INHIBITOR
Drug: duvelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (Kinase)
Gene: PIK3CB
UniProt: P42338 (PK3CB_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.07
Action type: INHIBITOR
Drug: duvelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Kinase)
Gene: PIK3CD
UniProt: O00329 (PK3CD_HUMAN)
Organism: Homo sapiens
Activity: Kd = 10.638
Action type: INHIBITOR
Assay: Enzymatic assay at 3mM ATP (nM)
Drug: duvelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Kinase)
Gene: PIK3CG
UniProt: P48736 (PK3CG_HUMAN)
Organism: Homo sapiens
Activity: Kd = 9.62
Action type: INHIBITOR
Assay: Enzymatic assay at 3mM ATP (nM)
Drug: dacomitinib
Target: Tyrosine-protein kinase JAK3 (Kinase)
Gene: JAK3
UniProt: P52333 (JAK3_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 5.45
Assay: Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA
Drug: dacomitinib
Target: Proto-oncogene tyrosine-protein kinase Src (Kinase)
Gene: SRC
UniProt: P12931 (SRC_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 6.96
Assay: Inhibition of Src (unknown origin)
Drug: dacomitinib
Target: Tyrosine-protein kinase Lck (Kinase)
Gene: LCK
UniProt: P06239 (LCK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.03
Assay: Inhibition of LCK (unknown origin)
Drug: dacomitinib
Target: Epidermal growth factor receptor (Kinase)
Gene: EGFR
UniProt: P00533 (EGFR_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.222
Action type: INHIBITOR
Assay: ELISA-Based erbB Kinase Assay with 20 uM [ATP]
Drug: dacomitinib
Target: Receptor tyrosine-protein kinase erbB-2 (Kinase)
Gene: ERBB2
UniProt: P04626 (ERBB2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.34
Action type: INHIBITOR
Assay: ELISA-Based erbB Kinase Assay with 20 uM [ATP]
Drug: dacomitinib
Target: Receptor tyrosine-protein kinase erbB-4 (Kinase)
Gene: ERBB4
UniProt: Q15303 (ERBB4_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.133
Action type: INHIBITOR
Assay: ELISA-Based erbB Kinase Assay with 20 uM [ATP]
Drug: talazoparib tosylate
Target: Poly [ADP-ribose] polymerase 2 (Enzyme)
Gene: PARP2
UniProt: Q9UGN5 (PARP2_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.06
Action type: INHIBITOR
Drug: talazoparib tosylate
Target: Poly [ADP-ribose] polymerase 1 (Enzyme)
Gene: PARP1
UniProt: P09874 (PARP1_HUMAN)
Organism: Homo sapiens
Activity: Ki = 8.921
Action type: INHIBITOR
Drug: baloxavir marboxil
Target: Polymerase acidic protein (Enzyme)
Gene: PA
UniProt: P03433 (PA_I34A1)
Organism: Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)
Activity: IC50 = 8.854
Action type: INHIBITOR
Drug: lorlatinib
Target: Tyrosine-protein kinase FRK (Kinase)
Gene: FRK
UniProt: P42685 (FRK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.28
Assay: Inhibition of FRK (unknown origin) by TR-FRET-based Z'-LYTE assay
Drug: lorlatinib
Target: ALK tyrosine kinase receptor (Kinase)
Gene: ALK
UniProt: Q9UM73 (ALK_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.959
Action type: INHIBITOR
Drug: lorlatinib
Target: Proto-oncogene tyrosine-protein kinase ROS (Kinase)
Gene: ROS1
UniProt: P08922 (ROS1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 9.301
Action type: INHIBITOR
Drug: lorlatinib
Target: Focal adhesion kinase 1 (Kinase)
Gene: PTK2
UniProt: Q05397 (FAK1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.77
Action type: INHIBITOR
Drug: lorlatinib
Target: High affinity nerve growth factor receptor (Kinase)
Gene: NTRK1
UniProt: P04629 (NTRK1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.62
Action type: INHIBITOR
Drug: lorlatinib
Target: Tyrosine-protein kinase Fer (Kinase)
Gene: FER
UniProt: P16591 (FER_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.481
Action type: INHIBITOR
Drug: lorlatinib
Target: Activated CDC42 kinase 1 (Kinase)
Gene: TNK2
UniProt: Q07912 (ACK1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.77
Action type: INHIBITOR
Drug: lorlatinib
Target: BDNF/NT-3 growth factors receptor (Kinase)
Gene: NTRK2
UniProt: Q16620 (NTRK2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.638
Action type: INHIBITOR
Drug: lorlatinib
Target: Protein-tyrosine kinase 2-beta (Kinase)
Gene: PTK2B
UniProt: Q14289 (FAK2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.854
Action type: INHIBITOR
Drug: lorlatinib
Target: NT-3 growth factor receptor (Kinase)
Gene: NTRK3
UniProt: Q16288 (NTRK3_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.337
Action type: INHIBITOR
Drug: lorlatinib
Target: Leukocyte tyrosine kinase receptor (Kinase)
Gene: LTK
UniProt: P29376 (LTK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.569
Action type: INHIBITOR
Drug: lorlatinib
Target: Tyrosine-protein kinase Fes/Fps (Kinase)
Gene: FES
UniProt: P07332 (FES_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.222
Action type: INHIBITOR
Drug: revefenacin
Target: Muscarinic acetylcholine receptor M1 (GPCR)
Gene: CHRM1
UniProt: P11229 (ACM1_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.38
Action type: ANTAGONIST
Drug: revefenacin
Target: Muscarinic acetylcholine receptor M2 (GPCR)
Gene: CHRM2
UniProt: P08172 (ACM2_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.52
Action type: ANTAGONIST
Drug: revefenacin
Target: Muscarinic acetylcholine receptor M3 (GPCR)
Gene: CHRM3
UniProt: P20309 (ACM3_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.75
Action type: ANTAGONIST
Drug: revefenacin
Target: Muscarinic acetylcholine receptor M4 (GPCR)
Gene: CHRM4
UniProt: P08173 (ACM4_HUMAN)
Organism: Homo sapiens
Activity: Ki = 9.26
Action type: ANTAGONIST
Drug: revefenacin
Target: Muscarinic acetylcholine receptor M5 (GPCR)
Gene: CHRM5
UniProt: P08912 (ACM5_HUMAN)
Organism: Homo sapiens
Activity: Ki = 8.2
Action type: ANTAGONIST
Drug: glasdegib
Target: Smoothened homolog (GPCR)
Gene: Smo
UniProt: P56726 (SMO_MOUSE)
Organism: Mus musculus
Activity: IC50 = 8.3
Assay: Inhibition of Smo in mouse C3H10T1/2 cells using human recombinant SHH assessed as effect on SMO/SHH transient transcriptional activation after 20 hrs by Gli-luciferase reporter assay
Drug: glasdegib
Target: Smoothened homolog (GPCR)
Gene: SMO
UniProt: Q99835 (SMO_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.301
Action type: ANTAGONIST
Drug: larotrectinib
Target: High affinity nerve growth factor receptor (Kinase)
Gene: NTRK1
UniProt: P04629 (NTRK1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.187
Action type: INHIBITOR
Drug: larotrectinib
Target: BDNF/NT-3 growth factors receptor (Kinase)
Gene: NTRK2
UniProt: Q16620 (NTRK2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.092
Action type: INHIBITOR
Drug: larotrectinib
Target: NT-3 growth factor receptor (Kinase)
Gene: NTRK3
UniProt: Q16288 (NTRK3_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.975
Action type: INHIBITOR
Drug: gilteritinib
Target: Proto-oncogene tyrosine-protein kinase receptor Ret (Kinase)
Gene: RET
UniProt: P07949 (RET_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.47
Assay: Inhibition Assay: A partial protein of only a kinase domain of RET protein was purchased from Carna Biosciences Inc., Japan. The phosphorylation activity toward a peptide substrate was investigated using an EZ reader (Caliper). Test compounds were each mixed with a protein solution to give 8 final concentrations from 100 nM to 0.03 nM, followed by addition of a mixed liquid of ATP and substrate peptide (Caliper) and reaction for 30 minutes. The ATP concentration used was 100 µM. A reaction liquid which contained protein but no test compound (in which the solvent DMSO alone was added at 0.8% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition. In the absence of the test compound, the phosphorylation peptide peak without ATP addition and with ATP addition was assumed to be 100% inhibition and 0% inhibition, respectively.
Drug: gilteritinib
Target: High affinity nerve growth factor receptor (Kinase)
Gene: NTRK1
UniProt: P04629 (NTRK1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.96
Action type: INHIBITOR
Drug: gilteritinib
Target: ALK tyrosine kinase receptor (Kinase)
Gene: ALK
UniProt: Q9UM73 (ALK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.82
Assay: Inhibition Assay: A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated, and injected into mouse lymphoid cell line BA/F3 cells. Using a magnetic bead reagent for cell separation and a purification column (anti-CD8 monoclonal antibody immobilized on magnetic beads and a MiniMACS purification column both are products of MilteDyi Biotec Inc.), cell surface CD8-expressing cells were purified to establish EML4-ALK fusion protein v1-expressing BA/F3 cells. From the cells, EML4-ALK fusion protein v1 was purified and subjected to kinase activity evaluation. EML4-ALK fusion protein v1 was investigated for its phosphorylation activity toward a peptide substrate by using a kinase activity detection kit (HTRF KinEASE-TK Cisbio Inc.). Test compounds were each added to a reaction solution containing the enzyme protein to give 8 final concentrations from 1000 nM to 0.3 nM, followed by addition of
Drug: gilteritinib
Target: Tyrosine-protein kinase receptor UFO (Kinase)
Gene: AXL
UniProt: P30530 (UFO_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 9.1
Action type: INHIBITOR
Drug: gilteritinib
Target: Leukocyte tyrosine kinase receptor (Kinase)
Gene: LTK
UniProt: P29376 (LTK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 9.7
Action type: INHIBITOR
Drug: gilteritinib
Target: Tyrosine-protein kinase Mer (Kinase)
Gene: MERTK
UniProt: Q12866 (MERTK_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.52
Action type: INHIBITOR
Drug: gilteritinib
Target: Proto-oncogene tyrosine-protein kinase ROS (Kinase)
Gene: ROS1
UniProt: P08922 (ROS1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.72
Assay: Inhibition Assay: A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Example 5, except that the ATP concentration in the mixed solution of ATP and substrate peptide (Caliper) was 50 uM. Test Example 5: A partial protein of only a kinase domain of RET protein was purchased from Carna Biosciences Inc., Japan. The phosphorylation activity toward a peptide substrate was investigated using an EZ reader (Caliper). Test compounds were each mixed with a protein solution to give 8 final concentrations from 100 nM to 0.03 nM, followed by addition of a mixed liquid of ATP and substrate peptide (Caliper) and reaction for 30 minutes. The ATP concentration used was 100 ÂµM. A reaction liquid which contained protein but no test compound (in which the solvent DMSO alone was added at 0.8% in place of the test compound) was prepared, followed by reaction in the same manner with or without ATP addition.
Drug: gilteritinib
Target: Receptor-type tyrosine-protein kinase FLT3 (Kinase)
Gene: FLT3
UniProt: P36888 (FLT3_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.301
Action type: INHIBITOR
Drug: evocalcet
Target: Extracellular calcium-sensing receptor (GPCR)
Gene: CASR
UniProt: P41180 (CASR_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 7.032
Action type: AGONIST
Drug: caplacizumab
Target: von Willebrand factor (Unclassified)
Gene: VWF
UniProt: P04275 (VWF_HUMAN)
Organism: Homo sapiens
Activity: Kd = 8.509
Action type: ANTIBODY BINDING
Drug: lanadelumab
Target: Plasma kallikrein (Enzyme)
Gene: KLKB1
UniProt: P03952 (KLKB1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 10.05
Action type: ANTIBODY BINDING
Drug: vibegron
Target: Beta-3 adrenergic receptor (GPCR)
Gene: Adrb3
UniProt: P26255 (ADRB3_RAT)
Organism: Rattus norvegicus
Activity: EC50 = 7.07
Assay: Agonist activity at rat beta3 adrenergic receptor expressed in CHO cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
Drug: vibegron
Target: Beta-3 adrenergic receptor (GPCR)
Gene: ADRB3
UniProt: O02662 (ADRB3_CANLF)
Organism: Canis lupus familiaris
Activity: EC50 = 7.96
Assay: Agonist activity at dog beta3 adrenergic receptor expressed in CHO cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
Drug: vibegron
Target: Beta-3 adrenergic receptor (GPCR)
Gene: ADRB3
UniProt: Q28524 (ADRB3_MACMU)
Organism: Macaca mulatta
Activity: EC50 = 9.24
Assay: Agonist activity at rhesus monkey beta3 adrenergic receptor expressed in CHO cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay
Drug: vibegron
Target: Beta-3 adrenergic receptor (GPCR)
Gene: ADRB3
UniProt: P13945 (ADRB3_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 8.959
Action type: AGONIST
Assay: Mechanism of Action
Drug: omidenepag isopropyl
Target: Prostaglandin E2 receptor EP2 subtype (GPCR)
Gene: PTGER2
UniProt: P43116 (PE2R2_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 8.081
Action type: AGONIST
Assay: activity measured for the active metabolite (omidenepag)
Drug: patisiran
Target: transthyretin (TTR) mRNA (RNA)
Gene: TTR
UniProt: P02766 (TTHY_HUMAN)
Organism: Homo sapiens
Action type: ANTISENSE INHIBITOR
Assay: Mechanism of Action
Drug: moxetumomab pasudotox
Target: B-cell receptor CD22 (Membrane receptor)
Gene: CD22
UniProt: P20273 (CD22_HUMAN)
Organism: Homo sapiens
Activity: Kd = 8.2
Action type: BINDING AGENT
Drug: fremanezumab
Target: Calcitonin gene-related peptide 1 (GPCR)
Gene: CALCA
UniProt: P06881 (CALCA_HUMAN)
Organism: Homo sapiens
Activity: Kd > 10.3
Action type: ANTIBODY BINDING
Drug: galcanezumab
Target: Calcitonin gene-related peptide 1 (GPCR)
Gene: CALCA
UniProt: P06881 (CALCA_HUMAN)
Organism: Homo sapiens
Activity: Kd = 8.7
Action type: ANTIBODY BINDING
Drug: cemiplimab
Target: Programmed cell death protein 1 (Membrane receptor)
Gene: PDCD1
UniProt: Q15116 (PDCD1_HUMAN)
Organism: Homo sapiens
Activity: Kd = 7.102
Action type: ANTIBODY BINDING
Drug: inotersen 
Target: transthyretin (TTR) mRNA (RNA)
Gene: TTR
UniProt: P02766 (TTHY_HUMAN)
Organism: Homo sapiens
Action type: ANTISENSE INHIBITOR
Assay: Mechanism of Action
Drug: emapalumab
Target: Interferon gamma (Cytokine)
Gene: IFNG
UniProt: P01579 (IFNG_HUMAN)
Organism: Homo sapiens
Activity: Kd = 9.1
Action type: ANTIBODY BINDING
Drug: ravulizumab
Target: Complement C5 (Secreted)
Gene: C5
UniProt: P01031 (CO5_HUMAN)
Organism: Homo sapiens
Activity: Kd = 9.357
Action type: ANTIBODY BINDING
Drug: tagraxofusp
Target: Interleukin-3 receptor (Membrane receptor)
Gene: IL3RA|CSF2RB
UniProt: P26951|P32927 (IL3RA_HUMAN|IL3RB_HUMAN)
Organism: Homo sapiens
Action type: BINDING AGENT
Drug: brexanolone
Target: Glucose-6-phosphate 1-dehydrogenase (Enzyme)
Gene: G6PD
UniProt: P11413 (G6PD_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 4.18
Assay: Inhibition of human recombinant N-terminal His tagged G6PD expressed in Escherichia coli JM109 (DE3) cells assessed as production of NADPH after 30 mins by Amplite fluorimetric assay
Drug: brexanolone
Target: GABA-A receptor alpha-1/beta-2/gamma-2 (Ion channel)
Gene: GABRA1|GABRG2|GABRB2
UniProt: P14867|P18507|P47870 (GBRA1_HUMAN|GBRG2_HUMAN|GBRB2_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 7.222
Action type: POSITIVE ALLOSTERIC MODULATOR
Assay: Possible target. Activity determined against recombinant Ltk cells
Drug: brexanolone
Target: GABA A receptor alpha-4/beta-3/delta (Ion channel)
Gene: GABRA4|GABRB3|GABRD
UniProt: P48169|P28472|O14764 (GBRA4_HUMAN|GBRB3_HUMAN|GBRD_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 7.097
Action type: POSITIVE ALLOSTERIC MODULATOR
Assay: Possible target. Activity determined against recombinant CHO cells
Drug: brexanolone
Target: GABA-A receptor alpha-6/beta-3/delta (Ion channel)
Gene: GABRA6|GABRB3|GABRD
UniProt: Q16445|P28472|O14764 (GBRA6_HUMAN|GBRB3_HUMAN|GBRD_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 6.81
Action type: POSITIVE ALLOSTERIC MODULATOR
Assay: Possible target. Activity determined against recombinant CHO cells
Drug: solriamfetol
Target: Sodium-dependent serotonin transporter (Transporter)
Gene: SLC6A4
UniProt: P31645 (SC6A4_HUMAN)
Organism: Homo sapiens
Activity: Ki = 4.088
Action type: INHIBITOR
Assay: Binding affinity
Drug: solriamfetol
Target: Sodium-dependent noradrenaline transporter (Transporter)
Gene: SLC6A2
UniProt: P23975 (SC6A2_HUMAN)
Organism: Homo sapiens
Activity: Ki = 5.432
Action type: INHIBITOR
Assay: Binding affinity
Drug: solriamfetol
Target: Sodium-dependent dopamine transporter (Transporter)
Gene: SLC6A3
UniProt: Q01959 (SC6A3_HUMAN)
Organism: Homo sapiens
Activity: Ki = 4.848
Action type: INHIBITOR
Assay: Binding affinity
Drug: siponimod
Target: Sphingosine 1-phosphate receptor 4 (GPCR)
Gene: S1PR4
UniProt: O95977 (S1PR4_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 6.125
Action type: MODULATOR
Drug: siponimod
Target: Sphingosine 1-phosphate receptor 3 (GPCR)
Gene: S1PR3
UniProt: Q99500 (S1PR3_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 3
Action type: MODULATOR
Drug: siponimod
Target: Sphingosine 1-phosphate receptor 2 (GPCR)
Gene: S1PR2
UniProt: O95136 (S1PR2_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 4
Action type: MODULATOR
Drug: siponimod
Target: Sphingosine 1-phosphate receptor 1 (GPCR)
Gene: S1PR1
UniProt: P21453 (S1PR1_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 9.409
Action type: MODULATOR
Assay: Possible mechanism of action
Drug: siponimod
Target: Sphingosine 1-phosphate receptor 5 (GPCR)
Gene: S1PR5
UniProt: Q9H228 (S1PR5_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 9.009
Action type: MODULATOR
Assay: Possible mechanism of action
Drug: erdafitinib
Target: Vascular endothelial growth factor receptor 2 (Kinase)
Gene: Kdr
UniProt: P35918 (VGFR2_MOUSE)
Organism: Mus musculus
Activity: IC50 = 10
Assay: Inhibition of VEGFR2 in mouse BAF3 cells
Drug: erdafitinib
Target: Vascular endothelial growth factor receptor 2 (Kinase)
Gene: KDR
UniProt: P35968 (VGFR2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.434
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: erdafitinib
Target: Fibroblast growth factor receptor 3 (Kinase)
Gene: FGFR3
UniProt: P22607 (FGFR3_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.523
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: erdafitinib
Target: Fibroblast growth factor receptor 1 (Kinase)
Gene: FGFR1
UniProt: P11362 (FGFR1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.921
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: erdafitinib
Target: Fibroblast growth factor receptor 2 (Kinase)
Gene: FGFR2
UniProt: P21802 (FGFR2_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.602
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: erdafitinib
Target: Fibroblast growth factor receptor 4 (Kinase)
Gene: FGFR4
UniProt: P22455 (FGFR4_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.244
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: alpelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (Kinase)
Gene: PIK3CD
UniProt: O00329 (PK3CD_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 6.54
Assay: Inhibition of P110delta (unknown origin) using PIP2:PS as substrate by TR-FRET assay
Drug: alpelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (Kinase)
Gene: PIK3CB
UniProt: P42338 (PK3CB_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 5.92
Assay: Inhibition of P110beta (unknown origin) using L-a-phosphatidylinositol as substrate by luminescence assay
Drug: alpelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (Kinase)
Gene: PIK3CG
UniProt: P48736 (PK3CG_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 6.6
Assay: Inhibition of P110gamma (unknown origin) using PIP2:PS as substrate by TR-FRET assay
Drug: alpelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (Kinase)
Gene: Pik3cb
UniProt: Q9Z1L0 (PK3CB_RAT)
Organism: Rattus norvegicus
Activity: IC50 = 5.66
Assay: Inhibition of PI3Kbeta in rat Rat1 cells assessed as reduction of Akt phosphorylation at Ser473 in presence of 0.5% fetal calf serum
Drug: alpelisib
Target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (Kinase)
Gene: PIK3CA
UniProt: P42336 (PK3CA_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 8.337
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: bremelanotide
Target: Melanocortin receptor 5 (GPCR)
Gene: MC5R
UniProt: P33032 (MC5R_HUMAN)
Organism: Homo sapiens
Activity: Ki = 7.77
Action type: AGONIST
Assay: Displacement of [125I]-NAD-alpha-MSH from human recombinant MC3 receptor human MC5 expressed in BHK570 cells after 1 hr in presence of ovalbumin
Drug: bremelanotide
Target: Melanocortin receptor 3 (GPCR)
Gene: MC3R
UniProt: P41968 (MC3R_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 8.62
Action type: AGONIST
Assay: Agonist activity at human MC3R expressed in low doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 45 mins by HTRF method
Drug: bremelanotide
Target: Melanocyte-stimulating hormone receptor (GPCR)
Gene: MC1R
UniProt: Q01726 (MSHR_HUMAN)
Organism: Homo sapiens
Activity: EC50 = 10.02
Action type: AGONIST
Assay: Agonist activity at human MC1R expressed in low doxycyclin-treated HEK293 cell membranes assessed as increase in cAMP production after 45 mins by HTRF method
Drug: bremelanotide
Target: Adrenocorticotropic hormone receptor (GPCR)
Gene: MC2R
UniProt: Q01718 (ACTHR_HUMAN)
Organism: Homo sapiens
Action type: AGONIST
Drug: bremelanotide
Target: Melanocortin receptor 4 (GPCR)
Gene: MC4R
UniProt: P32245 (MC4R_HUMAN)
Organism: Homo sapiens
Activity: Kd = 8
Action type: AGONIST
Assay: Functional evaluation of PT‐141 at the MC4R was performed by measuring the accumulation of intracellular cAMP in HEK‐293 cells expressing MC4R
Drug: selinexor
Target: Exportin-1 (Nuclear other)
Gene: XPO1
UniProt: O14980 (XPO1_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.7
Action type: INHIBITOR
Assay: Mechanism of Action
Drug: prabotulinumtoxinA
Target: Synaptosomal-associated protein 25 (Cytosolic other)
Gene: SNAP25
UniProt: P60880 (SNP25_HUMAN)
Organism: Homo sapiens
Action type: BLOCKER
Assay: Mechanism of Action
Drug: polatuzumab vedotin
Target: Tubulin beta (Tumour-associated antigen)
Gene: TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8
UniProt: P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7 (TBB5_HUMAN|TBB1_HUMAN|TBB2A_HUMAN|TBB2B_HUMAN|TBB3_HUMAN|TBB4A_HUMAN|TBB4B_HUMAN|TBB6_HUMAN|TBB8_HUMAN)
Organism: Homo sapiens
Action type: BINDING AGENT
Assay: Mechanism of Action
Drug: polatuzumab vedotin
Target: B-cell antigen receptor complex-associated protein beta chain (Tumour-associated antigen)
Gene: CD79B
UniProt: P40259 (CD79B_HUMAN)
Organism: Homo sapiens
Action type: ANTIBODY BINDING
Assay: Mechanism of Action
Drug: darolutamide
Target: Androgen receptor (Transcription factor)
Gene: Ar
UniProt: P15207 (ANDR_RAT)
Organism: Rattus norvegicus
Activity: Ki = 7.96
Action type: ANTAGONIST
Assay: Binding affinity measured in competition with [<sup>3</sup>H]mibolerone using wtAR isolated from rat ventral prostates.
Drug: darolutamide
Target: Progesterone receptor (Nuclear hormone receptor)
Gene: PGR
UniProt: P06401 (PRGR_HUMAN)
Organism: Homo sapiens
Action type: ANTAGONIST
Drug: darolutamide
Target: Androgen receptor (Nuclear hormone receptor)
Gene: AR
UniProt: P10275 (ANDR_HUMAN)
Organism: Homo sapiens
Activity: IC50 = 7.187
Action type: INHIBITOR
Assay: Competitively inhibits androgen binding
Drug: volanesorsen
Target: apolipoprotein C-III (apoC-III) mRNA (RNA)
Gene: APOC3
UniProt: P02656 (APOC3_HUMAN)
Organism: Homo sapiens
Action type: ANTISENSE INHIBITOR
Assay: Mechanism of Action
Drug: risankizumab
Target: Interleukin-23 subunit alpha (Cytokine)
Gene: IL23A
UniProt: Q9NPF7 (IL23A_HUMAN)
Organism: Homo sapiens
Activity: Kd = 11
Action type: INHIBITOR
Assay: selectively binds to the p19 subunit of human IL-23
Drug: ropeginterferon alfa-2b
Target: Interferon alpha/beta receptor (Membrane receptor)
Gene: IFNAR1|IFNAR2
UniProt: P17181|P48551 (INAR1_HUMAN|INAR2_HUMAN)
Organism: Homo sapiens
Action type: BINDING AGENT
Assay: Patients showed a statistically significant difference in the JAK2V617F allele burden (19.7%) and JAK2V617F allele change from baseline (-22.9%)